ArticleJournal of gastric cancer2026
Clinical Impact of Trastuzumab Deruxtecan in Patients With HER2-Positive Advanced Gastric Cancer and Ascites: Findings From the EN-DEAVOR Study.
Article in Journal of gastric cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposePatients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC) and ascites have poor prognosis and are often excluded from clinical trials. Thus, evidence on the effect of trastuzumab deruxtecan (T-DXd) in this population remains limited. MATERIALS AND
methodsThis subgroup analysis of the EN-DEAVOR (UMIN000049032) study assessed outcomes in patients with T-DXd-treated HER2-positive AGC from Japan, stratified by computed tomography-defined ascites severity: none (ascites not detected), low (confined to the upper or lower abdomen), moderate (neither low nor high), and high (diffusely present throughout the abdomen). The outcomes included overall survival (OS), real-world progression-free survival (rwPFS), ascites response rate, and incidence of grade ≥3 adverse events (AEs).
resultsAmong 312 patients, 173, 81, 34, and 20 had no, low, moderate, and high ascites severity, respectively. The median OS was 12.35, 6.77, 6.97, and 5.13 months, respectively, and the median rwPFS was 5.32, 3.68, 3.50, and 2.76 months, respectively, for the no, low, moderate, and high severity groups. The overall ascites response rate to ascites severity was 23.0%. The median OS and rwPFS were 11.83 (95% confidence interval [CI], 7.82-18.96) and 6.64 (95% CI, 4.17-9.56) months, respectively, in responders, and 6.28 (95% CI, 4.90-7.03) and 3.15 (95% CI, 2.17-3.94) months, respectively, in non-responders. Grade ≥3 AE incidence was comparable across subgroups.
conclusionsT-DXd demonstrated efficacy and a manageable safety profile in patients with HER2-positive AGC, including those with severe ascites. The ascites response correlated with improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.